Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki, Shun-Ichiro Komatsu, Atsushi Muto, Kei Nishimura, Momoko Okuda, Hisakazu Sanada, Motohiko Sato, Norihito Shibahara, Tetsuya Wakabayashi, Koji Yamaguchi, Akiko Matsusaki, Zenjiro Sampei, Hirotake Shiraiwa, Hiroko Konishi, Yoshiki Kawabe, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa
BACKGROUND: Emicizumab, a factor (F) VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment option for people with hemophilia A (PwHA). However, a small proportion of PwHA still experience bleeds even under emicizumab prophylaxis, as observed in the long-term outcomes of clinical studies. A more potent BsAb may be desirable for such patients. OBJECTIVES: To identify a potent BsAb to FIXa and FX, NXT007, surpassing emicizumab by in vitro and in vivo evaluation...
February 2024: Journal of Thrombosis and Haemostasis: JTH